세계의 동물용 백신 시장 보고서 : 백신 유형, 기술, 투여 경로, 유통 채널, 지역별(2024-2032년)

The global veterinary vaccines market size reached US$ 13.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 28.0 Billion by 2032, exhibiting a growth rate (CAGR) of 8.12% during 2024-2032.

Veterinary vaccines represent bio-prepared immunizations that are administered to domestic animals or wild species through parenteral and oral routes to stimulate protective immune responses without causing the disease itself. They involve inactivated, live attenuated and recombinant vaccines as some common medications. These inoculations aid in reducing animal suffering, enhancing immune efficiency, and preventing the risk of developing and transmitting various contagious zoonotic diseases. Apart from this, veterinary vaccines are cost-effective, reliable, and offer long-term prevention, due to which they are also used to increase the production of livestock across the globe.

Veterinary Vaccines Market Trends:

The global veterinary vaccines market is majorly driven by the increasing demand for effective immunization products and the rising prevalence of various infectious epizootic disorders. This can be further attributed to the domestication of both companion and livestock animals across the globe and the enhanced focus on pet health. In line with this, extensive investments by governments in the pharmaceutical sector to improve novel veterinary vaccine manufacturing procedures are acting as another growth-inducing factor. Additionally, the introduction of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) vaccines with improved product stability, efficacy, and route administration approach is contributing to the market growth. Besides this, the innovation of intramuscular needle-free vaccine injections and growing awareness amongst consumers regarding their beneficial properties, such as enhanced safety and less pain, is propelling the market growth. Moreover, the fueling need for veterinary vaccines to prevent the transmission of disease-carrying microbes from livestock-based products, including milk, meat, leather, eggs, and wool, is positively stimulating the market growth. Other factors, such as significant improvements in the healthcare infrastructure, ongoing research and development (R&D) activities, and strategic collaborations amongst key players to enhance the efficiency of veterinary vaccines, are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global veterinary vaccines market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on vaccine type, technology, route of administration and distribution channel.

Breakup by Vaccine Type:

Livestock Vaccines

Bovine Vaccines

Poultry Vaccines

Porcine Vaccines

Others

Companion Animal Vaccines

Canine Vaccines

Feline Vaccines

Equine Vaccines

Breakup by Technology:

Attenuated Live Vaccines

Inactivated Vaccines

Toxoid Vaccines

Recombinant Vaccines

Others

Breakup by Route of Administration:

Subcutaneous

Intramuscular

Intranasal

Breakup by Distribution Channel:

Veterinary Hospitals

Veterinary Clinics

Pharmacies and Drug Stores

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Boehringer Ingelheim International GmbH, Ceva Sante Animale, Elanco Animal Health Incorporated, Hester Biosciences Limited, HIPRA, Indian Immunologicals Limited, Merck & Co. Inc., Neogen Corporation, Phibro Animal Health Corporation, Virbac SA and Zoetis Inc.

Key Questions Answered in This Report:

• How has the global veterinary vaccines market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global veterinary vaccines market?
• What are the key regional markets?
• What is the breakup of the market based on the vaccine type?
• What is the breakup of the market based on the technology?
• What is the breakup of the market based on the route of administration?
• What is the breakup of the market based on the distribution channel?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global veterinary vaccines market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Veterinary Vaccines Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Vaccine Type

• 6.1 Livestock Vaccines
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Bovine Vaccines
    • 6.1.2.2 Poultry Vaccines
    • 6.1.2.3 Porcine Vaccines
    • 6.1.2.4 Others
  • 6.1.3 Market Forecast
• 6.2 Companion Animal Vaccines
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Canine Vaccines
    • 6.2.2.2 Feline Vaccines
    • 6.2.2.3 Equine Vaccines
  • 6.2.3 Market Forecast

7 Market Breakup by Technology

• 7.1 Attenuated Live Vaccines
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Inactivated Vaccines
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Toxoid Vaccines
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Recombinant Vaccines
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Route of Administration

• 8.1 Subcutaneous
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Intramuscular
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Intranasal
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

• 9.1 Veterinary Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Veterinary Clinics
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Pharmacies and Drug Stores
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Boehringer Ingelheim International GmbH
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 Ceva Sante Animale
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Elanco Animal Health Incorporated
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
  • 15.3.4 Hester Biosciences Limited
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
  • 15.3.5 HIPRA
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Indian Immunologicals Limited
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Merck & Co. Inc.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
  • 15.3.8 Neogen Corporation
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Phibro Animal Health Corporation
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Virbac SA
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
  • 15.3.11 Zoetis Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials